Thrive to leverage $257M series B to make case for broad access to CancerSEEK blood test

Racial and socioeconomic diversity and access are key focuses for Thrive as it readies to deploy its $257 million series B round to design and run a registrational trial for its multicancer blood diagnostic.

Casdin Capital and Section 32 co-led Thrive Earlier Detection Corp.’s financing, which comes a year after the company launched with a $110 million series A led by Third Rock and an exclusive license from Johns Hopkins University to its multi-analyte test CancerSEEK for early cancer detection.Nineteen other firms and companies participated in the series B (see “Thrive’s Backers”)...